#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Nonalcoholic fatty liver disease ( NAFLD ) represents the leading cause of progressive liver disorders worldwide , affecting between 20 % to 40 % of the adult population .
2-1	16-28	Nonalcoholic	abstract[3]	new[3]	appos	2-6[0_3]
2-2	29-34	fatty	abstract[3]	new[3]	_	_
2-3	35-40	liver	object|abstract[3]	new|new[3]	coref	2-14
2-4	41-48	disease	abstract[3]	new[3]	_	_
2-5	49-50	(	_	_	_	_
2-6	51-56	NAFLD	abstract	giv	coref	3-1
2-7	57-58	)	_	_	_	_
2-8	59-69	represents	_	_	_	_
2-9	70-73	the	abstract[5]	new[5]	_	_
2-10	74-81	leading	abstract[5]	new[5]	_	_
2-11	82-87	cause	abstract[5]	new[5]	_	_
2-12	88-90	of	abstract[5]	new[5]	_	_
2-13	91-102	progressive	abstract[5]|abstract[7]	new[5]|new[7]	_	_
2-14	103-108	liver	abstract[5]|object|abstract[7]	new[5]|giv|new[7]	coref	3-22
2-15	109-118	disorders	abstract[5]|abstract[7]	new[5]|new[7]	_	_
2-16	119-128	worldwide	_	_	_	_
2-17	129-130	,	_	_	_	_
2-18	131-140	affecting	_	_	_	_
2-19	141-148	between	_	_	_	_
2-20	149-151	20	abstract[8]	new[8]	_	_
2-21	152-153	%	abstract[8]	new[8]	_	_
2-22	154-156	to	_	_	_	_
2-23	157-159	40	abstract[9]	new[9]	_	_
2-24	160-161	%	abstract[9]	new[9]	_	_
2-25	162-164	of	abstract[9]	new[9]	_	_
2-26	165-168	the	abstract[9]|person[10]	new[9]|new[10]	_	_
2-27	169-174	adult	abstract[9]|person[10]	new[9]|new[10]	_	_
2-28	175-185	population	abstract[9]|person[10]	new[9]|new[10]	_	_
2-29	186-187	.	_	_	_	_

#Text=NAFLD is defined by increased hepatic fat accumulation not explained by alcohol abuse , and it encompasses a wide spectrum of liver injuries , ranging from simple steatosis ( >5 % of liver weight ) to its inflammatory form nonalcoholic steatohepatitis ( NASH ) .
3-1	188-193	NAFLD	abstract	giv	coref	5-1
3-2	194-196	is	_	_	_	_
3-3	197-204	defined	_	_	_	_
3-4	205-207	by	_	_	_	_
3-5	208-217	increased	abstract[13]	new[13]	ana	3-16[0_13]
3-6	218-225	hepatic	abstract[13]	new[13]	_	_
3-7	226-229	fat	substance|abstract[13]	new|new[13]	_	_
3-8	230-242	accumulation	abstract[13]	new[13]	_	_
3-9	243-246	not	abstract[13]	new[13]	_	_
3-10	247-256	explained	abstract[13]	new[13]	_	_
3-11	257-259	by	abstract[13]	new[13]	_	_
3-12	260-267	alcohol	abstract[13]|event[14]	new[13]|new[14]	_	_
3-13	268-273	abuse	abstract[13]|event[14]	new[13]|new[14]	_	_
3-14	274-275	,	_	_	_	_
3-15	276-279	and	_	_	_	_
3-16	280-282	it	abstract	giv	ana	3-37
3-17	283-294	encompasses	_	_	_	_
3-18	295-296	a	abstract[16]	new[16]	_	_
3-19	297-301	wide	abstract[16]	new[16]	_	_
3-20	302-310	spectrum	abstract[16]	new[16]	_	_
3-21	311-313	of	abstract[16]	new[16]	_	_
3-22	314-319	liver	abstract[16]|object|event[18]	new[16]|giv|new[18]	coref	3-33
3-23	320-328	injuries	abstract[16]|event[18]	new[16]|new[18]	_	_
3-24	329-330	,	abstract[16]|event[18]	new[16]|new[18]	_	_
3-25	331-338	ranging	abstract[16]|event[18]	new[16]|new[18]	_	_
3-26	339-343	from	abstract[16]|event[18]	new[16]|new[18]	_	_
3-27	344-350	simple	abstract[16]|event[18]|abstract[19]	new[16]|new[18]|new[19]	appos	3-30[20_19]
3-28	351-360	steatosis	abstract[16]|event[18]|abstract[19]	new[16]|new[18]|new[19]	_	_
3-29	361-362	(	_	_	_	_
3-30	363-365	>5	abstract[20]	giv[20]	coref	13-16[0_20]
3-31	366-367	%	abstract[20]	giv[20]	_	_
3-32	368-370	of	abstract[20]	giv[20]	_	_
3-33	371-376	liver	abstract[20]|object|abstract[22]	giv[20]|giv|new[22]	coref	8-8
3-34	377-383	weight	abstract[20]|abstract[22]	giv[20]|new[22]	_	_
3-35	384-385	)	_	_	_	_
3-36	386-388	to	_	_	_	_
3-37	389-392	its	abstract|abstract[24]	giv|new[24]	appos	3-40[25_24]
3-38	393-405	inflammatory	abstract[24]	new[24]	_	_
3-39	406-410	form	abstract[24]	new[24]	_	_
3-40	411-423	nonalcoholic	abstract[25]	giv[25]	appos	3-43[0_25]
3-41	424-439	steatohepatitis	abstract[25]	giv[25]	_	_
3-42	440-441	(	_	_	_	_
3-43	442-446	NASH	abstract	giv	coref	4-1
3-44	447-448	)	_	_	_	_
3-45	449-450	.	_	_	_	_

#Text=NASH may be complicated by the presence of fibrosis and , eventually , it may progress to cirrhosis and hepatocellular carcinoma ( HCC ) .
4-1	451-455	NASH	abstract	giv	coref	5-52
4-2	456-459	may	_	_	_	_
4-3	460-462	be	_	_	_	_
4-4	463-474	complicated	_	_	_	_
4-5	475-477	by	_	_	_	_
4-6	478-481	the	abstract[28]	new[28]	ana	4-14[0_28]
4-7	482-490	presence	abstract[28]	new[28]	_	_
4-8	491-493	of	abstract[28]	new[28]	_	_
4-9	494-502	fibrosis	abstract[28]|object	new[28]|new	coref	5-54
4-10	503-506	and	_	_	_	_
4-11	507-508	,	_	_	_	_
4-12	509-519	eventually	_	_	_	_
4-13	520-521	,	_	_	_	_
4-14	522-524	it	abstract	giv	coref	20-26[204_0]
4-15	525-528	may	_	_	_	_
4-16	529-537	progress	_	_	_	_
4-17	538-540	to	_	_	_	_
4-18	541-550	cirrhosis	abstract	new	_	_
4-19	551-554	and	_	_	_	_
4-20	555-569	hepatocellular	substance[32]	new[32]	_	_
4-21	570-579	carcinoma	substance[32]	new[32]	_	_
4-22	580-581	(	_	_	_	_
4-23	582-585	HCC	abstract	new	_	_
4-24	586-587	)	_	_	_	_
4-25	588-589	.	_	_	_	_

#Text=NAFLD has a strong inherited component , and variants in proteins regulating hepatocellular lipid handling , including patatin-like phospholipase domain-containing 3 ( PNPLA3 ) , transmembrane 6 superfamily member 2 ( TM6SF2 ) , membrane bound O-acyltransferase domain-containing 7 ( MBOAT7 ) , predispose to the disease development and progression to NASH and fibrosis .
5-1	590-595	NAFLD	abstract	giv	coref	5-47
5-2	596-599	has	_	_	_	_
5-3	600-601	a	abstract[35]	new[35]	_	_
5-4	602-608	strong	abstract[35]	new[35]	_	_
5-5	609-618	inherited	abstract[35]	new[35]	_	_
5-6	619-628	component	abstract[35]	new[35]	_	_
5-7	629-630	,	_	_	_	_
5-8	631-634	and	_	_	_	_
5-9	635-643	variants	abstract[36]	new[36]	coref	9-18[81_36]
5-10	644-646	in	abstract[36]	new[36]	_	_
5-11	647-655	proteins	abstract[36]|substance[37]	new[36]|new[37]	coref	10-23[97_37]
5-12	656-666	regulating	abstract[36]|substance[37]	new[36]|new[37]	_	_
5-13	667-681	hepatocellular	abstract[36]|substance[37]|abstract[39]	new[36]|new[37]|new[39]	_	_
5-14	682-687	lipid	abstract[36]|substance[37]|abstract|abstract[39]	new[36]|new[37]|new|new[39]	coref	22-18
5-15	688-696	handling	abstract[36]|substance[37]|abstract[39]	new[36]|new[37]|new[39]	_	_
5-16	697-698	,	abstract[36]	new[36]	_	_
5-17	699-708	including	abstract[36]	new[36]	_	_
5-18	709-721	patatin-like	abstract[36]|abstract	new[36]|new	_	_
5-19	722-735	phospholipase	abstract[36]|abstract	new[36]|new	_	_
5-20	736-753	domain-containing	abstract[36]	new[36]	_	_
5-21	754-755	3	abstract[36]	new[36]	_	_
5-22	756-757	(	_	_	_	_
5-23	758-764	PNPLA3	abstract	new	_	_
5-24	765-766	)	_	_	_	_
5-25	767-768	,	_	_	_	_
5-26	769-782	transmembrane	person[43]	new[43]	_	_
5-27	783-784	6	person[43]	new[43]	_	_
5-28	785-796	superfamily	person[43]	new[43]	_	_
5-29	797-803	member	person[43]	new[43]	_	_
5-30	804-805	2	person[43]	new[43]	_	_
5-31	806-807	(	_	_	_	_
5-32	808-814	TM6SF2	abstract	new	_	_
5-33	815-816	)	_	_	_	_
5-34	817-818	,	_	_	_	_
5-35	819-827	membrane	_	_	_	_
5-36	828-833	bound	_	_	_	_
5-37	834-851	O-acyltransferase	abstract	new	_	_
5-38	852-869	domain-containing	_	_	_	_
5-39	870-871	7	_	_	_	_
5-40	872-873	(	_	_	_	_
5-41	874-880	MBOAT7	abstract	new	_	_
5-42	881-882	)	_	_	_	_
5-43	883-884	,	_	_	_	_
5-44	885-895	predispose	_	_	_	_
5-45	896-898	to	_	_	_	_
5-46	899-902	the	event[48]	new[48]	coref	6-20[61_48]
5-47	903-910	disease	abstract|event[48]	giv|new[48]	coref	6-20
5-48	911-922	development	event[48]	new[48]	_	_
5-49	923-926	and	_	_	_	_
5-50	927-938	progression	event[49]	new[49]	coref	13-19[130_49]
5-51	939-941	to	event[49]	new[49]	_	_
5-52	942-946	NASH	event[49]|abstract	new[49]|giv	coref	9-15
5-53	947-950	and	event[49]	new[49]	_	_
5-54	951-959	fibrosis	event[49]|object	new[49]|giv	coref	8-8[73_0]
5-55	960-961	.	_	_	_	_

#Text=Dietary habits such as excessive caloric intake , fructose consumption , and physical inactivity represent other risk factors for NAFLD development .
6-1	962-969	Dietary	abstract[52]	new[52]	_	_
6-2	970-976	habits	abstract[52]	new[52]	_	_
6-3	977-981	such	abstract[52]	new[52]	_	_
6-4	982-984	as	abstract[52]	new[52]	_	_
6-5	985-994	excessive	abstract[52]|event[54]	new[52]|new[54]	ana	7-4[0_54]
6-6	995-1002	caloric	abstract[52]|substance|event[54]	new[52]|new|new[54]	_	_
6-7	1003-1009	intake	abstract[52]|event[54]	new[52]|new[54]	_	_
6-8	1010-1011	,	abstract[52]	new[52]	_	_
6-9	1012-1020	fructose	abstract[52]|abstract|event[56]	new[52]|new|new[56]	_	_
6-10	1021-1032	consumption	abstract[52]|event[56]	new[52]|new[56]	_	_
6-11	1033-1034	,	abstract[52]	new[52]	_	_
6-12	1035-1038	and	abstract[52]	new[52]	_	_
6-13	1039-1047	physical	abstract[52]|event[57]	new[52]|new[57]	_	_
6-14	1048-1058	inactivity	abstract[52]|event[57]	new[52]|new[57]	_	_
6-15	1059-1068	represent	_	_	_	_
6-16	1069-1074	other	abstract[59]	new[59]	coref	13-8[123_59]
6-17	1075-1079	risk	abstract|abstract[59]	new|new[59]	_	_
6-18	1080-1087	factors	abstract[59]	new[59]	_	_
6-19	1088-1091	for	abstract[59]	new[59]	_	_
6-20	1092-1097	NAFLD	abstract[59]|abstract|event[61]	new[59]|giv|giv[61]	coref|coref	8-15|9-29[87_61]
6-21	1098-1109	development	abstract[59]|event[61]	new[59]|giv[61]	_	_
6-22	1110-1111	.	_	_	_	_

#Text=In addition , its pathogenesis is closely intertwined with excessive adiposity , insulin resistance ( IR ) , and metabolic syndrome .
7-1	1112-1114	In	_	_	_	_
7-2	1115-1123	addition	_	_	_	_
7-3	1124-1125	,	_	_	_	_
7-4	1126-1129	its	event|abstract[63]	giv|new[63]	coref	11-5[102_63]
7-5	1130-1142	pathogenesis	abstract[63]	new[63]	_	_
7-6	1143-1145	is	_	_	_	_
7-7	1146-1153	closely	_	_	_	_
7-8	1154-1165	intertwined	_	_	_	_
7-9	1166-1170	with	_	_	_	_
7-10	1171-1180	excessive	abstract[64]	new[64]	_	_
7-11	1181-1190	adiposity	abstract[64]	new[64]	_	_
7-12	1191-1192	,	_	_	_	_
7-13	1193-1200	insulin	substance|abstract[66]	new|new[66]	appos|coref	7-16[0_66]|9-22
7-14	1201-1211	resistance	abstract[66]	new[66]	_	_
7-15	1212-1213	(	_	_	_	_
7-16	1214-1216	IR	abstract	giv	coref	8-1
7-17	1217-1218	)	_	_	_	_
7-18	1219-1220	,	_	_	_	_
7-19	1221-1224	and	_	_	_	_
7-20	1225-1234	metabolic	person|abstract[69]	new|new[69]	_	_
7-21	1235-1243	syndrome	abstract[69]	new[69]	_	_
7-22	1244-1245	.	_	_	_	_

#Text=IR even correlates with the severity of liver fibrosis , the main determinant of NAFLD prognosis .
8-1	1246-1248	IR	abstract	giv	coref	10-4
8-2	1249-1253	even	_	_	_	_
8-3	1254-1264	correlates	_	_	_	_
8-4	1265-1269	with	_	_	_	_
8-5	1270-1273	the	abstract[71]	new[71]	_	_
8-6	1274-1282	severity	abstract[71]	new[71]	_	_
8-7	1283-1285	of	abstract[71]	new[71]	_	_
8-8	1286-1291	liver	abstract[71]|object|object[73]	new[71]|giv|giv[73]	coref|coref	9-3[0_73]|14-20
8-9	1292-1300	fibrosis	abstract[71]|object[73]	new[71]|giv[73]	_	_
8-10	1301-1302	,	_	_	_	_
8-11	1303-1306	the	abstract[74]	new[74]	_	_
8-12	1307-1311	main	abstract[74]	new[74]	_	_
8-13	1312-1323	determinant	abstract[74]	new[74]	_	_
8-14	1324-1326	of	abstract[74]	new[74]	_	_
8-15	1327-1332	NAFLD	abstract[74]|abstract|abstract[76]	new[74]|giv|new[76]	coref	9-11
8-16	1333-1342	prognosis	abstract[74]|abstract[76]	new[74]|new[76]	_	_
8-17	1343-1344	.	_	_	_	_

#Text=Indeed , fibrosis has been observed in diabetic patients with NAFLD even independently of NASH , and genetic variants that impair insulin receptor ( InsR ) signaling favor fibrosis development in NAFLD patients .
9-1	1345-1351	Indeed	_	_	_	_
9-2	1352-1353	,	_	_	_	_
9-3	1354-1362	fibrosis	object	giv	coref	9-29
9-4	1363-1366	has	_	_	_	_
9-5	1367-1371	been	_	_	_	_
9-6	1372-1380	observed	_	_	_	_
9-7	1381-1383	in	_	_	_	_
9-8	1384-1392	diabetic	person[78]	new[78]	coref	9-32[89_78]
9-9	1393-1401	patients	person[78]	new[78]	_	_
9-10	1402-1406	with	person[78]	new[78]	_	_
9-11	1407-1412	NAFLD	person[78]|abstract	new[78]|giv	coref	9-32
9-12	1413-1417	even	_	_	_	_
9-13	1418-1431	independently	_	_	_	_
9-14	1432-1434	of	_	_	_	_
9-15	1435-1439	NASH	abstract	giv	coref	18-11
9-16	1440-1441	,	_	_	_	_
9-17	1442-1445	and	_	_	_	_
9-18	1446-1453	genetic	abstract[81]	giv[81]	_	_
9-19	1454-1462	variants	abstract[81]	giv[81]	_	_
9-20	1463-1467	that	abstract[81]	giv[81]	_	_
9-21	1468-1474	impair	abstract[81]	giv[81]	_	_
9-22	1475-1482	insulin	abstract[81]|substance|abstract[83]|abstract[85]	giv[81]|giv|new[83]|new[85]	appos|coref|coref	9-25[0_83]|17-11|18-40[184_85]
9-23	1483-1491	receptor	abstract[81]|abstract[83]|abstract[85]	giv[81]|new[83]|new[85]	_	_
9-24	1492-1493	(	abstract[81]|abstract[85]	giv[81]|new[85]	_	_
9-25	1494-1498	InsR	abstract[81]|abstract|abstract[85]	giv[81]|giv|new[85]	coref	18-30
9-26	1499-1500	)	abstract[81]|abstract[85]	giv[81]|new[85]	_	_
9-27	1501-1510	signaling	abstract[81]|abstract[85]	giv[81]|new[85]	_	_
9-28	1511-1516	favor	_	_	_	_
9-29	1517-1525	fibrosis	object|event[87]	giv|giv[87]	coref	10-6
9-30	1526-1537	development	event[87]	giv[87]	_	_
9-31	1538-1540	in	event[87]	giv[87]	_	_
9-32	1541-1546	NAFLD	event[87]|abstract|person[89]	giv[87]|giv|giv[89]	coref|coref	11-5|18-17[0_89]
9-33	1547-1555	patients	event[87]|person[89]	giv[87]|giv[89]	_	_
9-34	1556-1557	.	_	_	_	_

#Text=The mechanism whereby IR aggravates fibrosis may be related to reduced extracellular matrix ( ECM ) degradation and to the induction of proteins involved in collagen crosslinking .
10-1	1558-1561	The	abstract[90]	new[90]	_	_
10-2	1562-1571	mechanism	abstract[90]	new[90]	_	_
10-3	1572-1579	whereby	abstract[90]	new[90]	_	_
10-4	1580-1582	IR	abstract[90]|abstract	new[90]|giv	coref	15-24
10-5	1583-1593	aggravates	abstract[90]	new[90]	_	_
10-6	1594-1602	fibrosis	abstract[90]|object	new[90]|giv	coref	13-22
10-7	1603-1606	may	_	_	_	_
10-8	1607-1609	be	_	_	_	_
10-9	1610-1617	related	_	_	_	_
10-10	1618-1620	to	_	_	_	_
10-11	1621-1628	reduced	event[95]	new[95]	_	_
10-12	1629-1642	extracellular	substance[93]|event[95]	new[93]|new[95]	_	_
10-13	1643-1649	matrix	substance[93]|event[95]	new[93]|new[95]	_	_
10-14	1650-1651	(	event[95]	new[95]	_	_
10-15	1652-1655	ECM	abstract|event[95]	new|new[95]	_	_
10-16	1656-1657	)	event[95]	new[95]	_	_
10-17	1658-1669	degradation	event[95]	new[95]	_	_
10-18	1670-1673	and	_	_	_	_
10-19	1674-1676	to	_	_	_	_
10-20	1677-1680	the	event[96]	new[96]	_	_
10-21	1681-1690	induction	event[96]	new[96]	_	_
10-22	1691-1693	of	event[96]	new[96]	_	_
10-23	1694-1702	proteins	event[96]|substance[97]	new[96]|giv[97]	_	_
10-24	1703-1711	involved	event[96]|substance[97]	new[96]|giv[97]	_	_
10-25	1712-1714	in	event[96]|substance[97]	new[96]|giv[97]	_	_
10-26	1715-1723	collagen	event[96]|substance[97]|organization|abstract[99]	new[96]|giv[97]|new|new[99]	_	_
10-27	1724-1736	crosslinking	event[96]|substance[97]|abstract[99]	new[96]|giv[97]|new[99]	_	_
10-28	1737-1738	.	_	_	_	_

#Text=A new perspective of NAFLD pathogenesis and management is provided by epigenetics , which modulate transcriptome in response to environmental cues .
11-1	1739-1740	A	abstract[100]	new[100]	_	_
11-2	1741-1744	new	abstract[100]	new[100]	_	_
11-3	1745-1756	perspective	abstract[100]	new[100]	_	_
11-4	1757-1759	of	abstract[100]	new[100]	_	_
11-5	1760-1765	NAFLD	abstract[100]|abstract|abstract[102]	new[100]|giv|giv[102]	coref	13-19
11-6	1766-1778	pathogenesis	abstract[100]|abstract[102]	new[100]|giv[102]	_	_
11-7	1779-1782	and	abstract[100]	new[100]	_	_
11-8	1783-1793	management	abstract[100]|person	new[100]|new	_	_
11-9	1794-1796	is	_	_	_	_
11-10	1797-1805	provided	_	_	_	_
11-11	1806-1808	by	_	_	_	_
11-12	1809-1820	epigenetics	abstract[104]	new[104]	_	_
11-13	1821-1822	,	abstract[104]	new[104]	_	_
11-14	1823-1828	which	abstract[104]	new[104]	_	_
11-15	1829-1837	modulate	abstract[104]	new[104]	_	_
11-16	1838-1851	transcriptome	abstract[104]|abstract	new[104]|new	_	_
11-17	1852-1854	in	abstract[104]	new[104]	_	_
11-18	1855-1863	response	abstract[104]	new[104]	_	_
11-19	1864-1866	to	abstract[104]	new[104]	_	_
11-20	1867-1880	environmental	abstract[104]|abstract[106]	new[104]|new[106]	_	_
11-21	1881-1885	cues	abstract[104]|abstract[106]	new[104]|new[106]	_	_
11-22	1886-1887	.	_	_	_	_

#Text=In particular , microRNAs ( miRNAs ) are short non-protein coding , single-strand RNAs of 19 – 22 nucleotides that regulate gene expression and cell-to-cell communication as it occurs between hepatocytes and hepatic stellate cells ( HSCs ) during fibrogenesis .
12-1	1888-1890	In	_	_	_	_
12-2	1891-1901	particular	_	_	_	_
12-3	1902-1903	,	_	_	_	_
12-4	1904-1913	microRNAs	object	new	coref	12-9[109_0]
12-5	1914-1915	(	_	_	_	_
12-6	1916-1922	miRNAs	abstract	new	coref	16-8[156_0]
12-7	1923-1924	)	_	_	_	_
12-8	1925-1928	are	_	_	_	_
12-9	1929-1934	short	object[109]	giv[109]	_	_
12-10	1935-1946	non-protein	object[109]	giv[109]	_	_
12-11	1947-1953	coding	object[109]	giv[109]	_	_
12-12	1954-1955	,	object[109]	giv[109]	_	_
12-13	1956-1969	single-strand	object[109]	giv[109]	_	_
12-14	1970-1974	RNAs	object[109]	giv[109]	_	_
12-15	1975-1977	of	object[109]	giv[109]	_	_
12-16	1978-1980	19	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-17	1981-1982	–	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-18	1983-1985	22	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-19	1986-1997	nucleotides	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-20	1998-2002	that	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-21	2003-2011	regulate	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-22	2012-2016	gene	object[109]|abstract[110]|abstract|abstract[112]	giv[109]|new[110]|new|new[112]	coref	13-3[122_112]
12-23	2017-2027	expression	object[109]|abstract[110]|abstract[112]	giv[109]|new[110]|new[112]	_	_
12-24	2028-2031	and	object[109]|abstract[110]	giv[109]|new[110]	_	_
12-25	2032-2044	cell-to-cell	object[109]|abstract[110]|event[113]	giv[109]|new[110]|new[113]	ana	12-28[0_113]
12-26	2045-2058	communication	object[109]|abstract[110]|event[113]	giv[109]|new[110]|new[113]	_	_
12-27	2059-2061	as	_	_	_	_
12-28	2062-2064	it	event	giv	_	_
12-29	2065-2071	occurs	_	_	_	_
12-30	2072-2079	between	_	_	_	_
12-31	2080-2091	hepatocytes	animal	new	coref	21-13
12-32	2092-2095	and	_	_	_	_
12-33	2096-2103	hepatic	animal[117]	new[117]	coref	20-12[200_117]
12-34	2104-2112	stellate	substance|animal[117]	new|new[117]	_	_
12-35	2113-2118	cells	animal[117]	new[117]	_	_
12-36	2119-2120	(	_	_	_	_
12-37	2121-2125	HSCs	abstract	new	coref	16-15[158_0]
12-38	2126-2127	)	_	_	_	_
12-39	2128-2134	during	_	_	_	_
12-40	2135-2147	fibrogenesis	abstract	new	coref	22-24
12-41	2148-2149	.	_	_	_	_

#Text=Alteration of miRNA expression in response to genetic/epigenetic factors or environmental conditions may contribute to steatosis onset and NAFLD progression to fibrosis and cancer , mirroring the histological features and the molecular events occurring in NAFLD .
13-1	2150-2160	Alteration	abstract[120]	new[120]	_	_
13-2	2161-2163	of	abstract[120]	new[120]	_	_
13-3	2164-2169	miRNA	abstract[120]|abstract|abstract[122]	new[120]|new|giv[122]	coref|coref	18-19[176_122]|20-31
13-4	2170-2180	expression	abstract[120]|abstract[122]	new[120]|giv[122]	_	_
13-5	2181-2183	in	abstract[120]	new[120]	_	_
13-6	2184-2192	response	abstract[120]	new[120]	_	_
13-7	2193-2195	to	abstract[120]	new[120]	_	_
13-8	2196-2214	genetic/epigenetic	abstract[120]|abstract[123]|abstract[124]	new[120]|giv[123]|giv[124]	coref|coref	13-8[124_123]|15-13[150_124]
13-9	2215-2222	factors	abstract[120]|abstract[123]|abstract[124]	new[120]|giv[123]|giv[124]	_	_
13-10	2223-2225	or	abstract[120]|abstract[124]	new[120]|giv[124]	_	_
13-11	2226-2239	environmental	abstract[120]|abstract[124]|abstract[125]	new[120]|giv[124]|new[125]	_	_
13-12	2240-2250	conditions	abstract[120]|abstract[124]|abstract[125]	new[120]|giv[124]|new[125]	_	_
13-13	2251-2254	may	_	_	_	_
13-14	2255-2265	contribute	_	_	_	_
13-15	2266-2268	to	_	_	_	_
13-16	2269-2278	steatosis	abstract|event[127]|event[128]	giv|new[127]|new[128]	coref	13-31[135_128]
13-17	2279-2284	onset	event[127]|event[128]	new[127]|new[128]	_	_
13-18	2285-2288	and	event[128]	new[128]	_	_
13-19	2289-2294	NAFLD	event[128]|abstract|event[130]	new[128]|giv|giv[130]	coref|coref	13-36|14-33[146_130]
13-20	2295-2306	progression	event[128]|event[130]	new[128]|giv[130]	_	_
13-21	2307-2309	to	event[128]|event[130]	new[128]|giv[130]	_	_
13-22	2310-2318	fibrosis	event[128]|event[130]|object	new[128]|giv[130]|giv	coref	16-22[162_0]
13-23	2319-2322	and	event[128]|event[130]	new[128]|giv[130]	_	_
13-24	2323-2329	cancer	event[128]|event[130]|abstract	new[128]|giv[130]|new	coref	22-27
13-25	2330-2331	,	_	_	_	_
13-26	2332-2341	mirroring	_	_	_	_
13-27	2342-2345	the	abstract[133]|abstract[134]	new[133]|new[134]	ana	14-3[0_134]
13-28	2346-2358	histological	abstract[133]|abstract[134]	new[133]|new[134]	_	_
13-29	2359-2367	features	abstract[133]|abstract[134]	new[133]|new[134]	_	_
13-30	2368-2371	and	abstract[134]	new[134]	_	_
13-31	2372-2375	the	abstract[134]|event[135]	new[134]|giv[135]	_	_
13-32	2376-2385	molecular	abstract[134]|event[135]	new[134]|giv[135]	_	_
13-33	2386-2392	events	abstract[134]|event[135]	new[134]|giv[135]	_	_
13-34	2393-2402	occurring	abstract[134]|event[135]	new[134]|giv[135]	_	_
13-35	2403-2405	in	abstract[134]|event[135]	new[134]|giv[135]	_	_
13-36	2406-2411	NAFLD	abstract[134]|event[135]|abstract	new[134]|giv[135]|giv	coref	14-34
13-37	2412-2413	.	_	_	_	_

#Text=Thus , they could be exploited as attractive candidate biomarkers for an accurate profiling of the different stages of liver injury , enabling early and non-invasive diagnosis and the clinical monitoring of the disease progression .
14-1	2414-2418	Thus	_	_	_	_
14-2	2419-2420	,	_	_	_	_
14-3	2421-2425	they	abstract	giv	_	_
14-4	2426-2431	could	_	_	_	_
14-5	2432-2434	be	_	_	_	_
14-6	2435-2444	exploited	_	_	_	_
14-7	2445-2447	as	_	_	_	_
14-8	2448-2458	attractive	abstract[138]	new[138]	_	_
14-9	2459-2468	candidate	abstract[138]	new[138]	_	_
14-10	2469-2479	biomarkers	abstract[138]	new[138]	_	_
14-11	2480-2483	for	abstract[138]	new[138]	_	_
14-12	2484-2486	an	abstract[138]|abstract[139]	new[138]|new[139]	_	_
14-13	2487-2495	accurate	abstract[138]|abstract[139]	new[138]|new[139]	_	_
14-14	2496-2505	profiling	abstract[138]|abstract[139]	new[138]|new[139]	_	_
14-15	2506-2508	of	abstract[138]|abstract[139]	new[138]|new[139]	_	_
14-16	2509-2512	the	abstract[138]|abstract[139]|abstract[140]	new[138]|new[139]|new[140]	_	_
14-17	2513-2522	different	abstract[138]|abstract[139]|abstract[140]	new[138]|new[139]|new[140]	_	_
14-18	2523-2529	stages	abstract[138]|abstract[139]|abstract[140]	new[138]|new[139]|new[140]	_	_
14-19	2530-2532	of	abstract[138]|abstract[139]|abstract[140]	new[138]|new[139]|new[140]	_	_
14-20	2533-2538	liver	abstract[138]|abstract[139]|abstract[140]|object|event[142]	new[138]|new[139]|new[140]|giv|new[142]	coref	16-22
14-21	2539-2545	injury	abstract[138]|abstract[139]|abstract[140]|event[142]	new[138]|new[139]|new[140]|new[142]	_	_
14-22	2546-2547	,	_	_	_	_
14-23	2548-2556	enabling	_	_	_	_
14-24	2557-2562	early	abstract[143]	new[143]	_	_
14-25	2563-2566	and	abstract[143]	new[143]	_	_
14-26	2567-2579	non-invasive	abstract[143]	new[143]	_	_
14-27	2580-2589	diagnosis	abstract[143]	new[143]	_	_
14-28	2590-2593	and	_	_	_	_
14-29	2594-2597	the	event[144]	new[144]	_	_
14-30	2598-2606	clinical	event[144]	new[144]	_	_
14-31	2607-2617	monitoring	event[144]	new[144]	_	_
14-32	2618-2620	of	event[144]	new[144]	_	_
14-33	2621-2624	the	event[144]|event[146]	new[144]|giv[146]	_	_
14-34	2625-2632	disease	event[144]|abstract|event[146]	new[144]|giv|giv[146]	coref	15-18[151_0]
14-35	2633-2644	progression	event[144]|event[146]	new[144]|giv[146]	_	_
14-36	2645-2646	.	_	_	_	_

#Text=Therefore , we aimed to explore the mechanisms through which epigenetics and environmental factors interact to promote progressive NAFLD in the context of IR .
15-1	2647-2656	Therefore	_	_	_	_
15-2	2657-2658	,	_	_	_	_
15-3	2659-2661	we	person	acc	ana	16-5
15-4	2662-2667	aimed	_	_	_	_
15-5	2668-2670	to	_	_	_	_
15-6	2671-2678	explore	_	_	_	_
15-7	2679-2682	the	abstract[148]	new[148]	_	_
15-8	2683-2693	mechanisms	abstract[148]	new[148]	_	_
15-9	2694-2701	through	abstract[148]	new[148]	_	_
15-10	2702-2707	which	abstract[148]	new[148]	_	_
15-11	2708-2719	epigenetics	abstract[148]|abstract	new[148]|new	_	_
15-12	2720-2723	and	abstract[148]	new[148]	_	_
15-13	2724-2737	environmental	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
15-14	2738-2745	factors	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
15-15	2746-2754	interact	abstract[148]	new[148]	_	_
15-16	2755-2757	to	_	_	_	_
15-17	2758-2765	promote	_	_	_	_
15-18	2766-2777	progressive	abstract[151]	giv[151]	coref	18-49[0_151]
15-19	2778-2783	NAFLD	abstract[151]	giv[151]	_	_
15-20	2784-2786	in	_	_	_	_
15-21	2787-2790	the	abstract[152]	new[152]	_	_
15-22	2791-2798	context	abstract[152]	new[152]	_	_
15-23	2799-2801	of	abstract[152]	new[152]	_	_
15-24	2802-2804	IR	abstract[152]|abstract	new[152]|giv	coref	16-13
15-25	2805-2806	.	_	_	_	_

#Text=To this purpose , we first assessed which miRNAs were deregulated by IR in HSCs whose activation represents the hallmark of liver fibrosis .
16-1	2807-2809	To	_	_	_	_
16-2	2810-2814	this	abstract[154]	new[154]	_	_
16-3	2815-2822	purpose	abstract[154]	new[154]	_	_
16-4	2823-2824	,	_	_	_	_
16-5	2825-2827	we	person	giv	ana	17-3
16-6	2828-2833	first	_	_	_	_
16-7	2834-2842	assessed	_	_	_	_
16-8	2843-2848	which	abstract[156]	giv[156]	coref	17-6[164_156]
16-9	2849-2855	miRNAs	abstract[156]	giv[156]	_	_
16-10	2856-2860	were	_	_	_	_
16-11	2861-2872	deregulated	_	_	_	_
16-12	2873-2875	by	_	_	_	_
16-13	2876-2878	IR	abstract	giv	coref	18-9
16-14	2879-2881	in	_	_	_	_
16-15	2882-2886	HSCs	abstract[158]	giv[158]	coref	17-11[166_158]
16-16	2887-2892	whose	abstract[158]|abstract[159]	giv[158]|new[159]	_	_
16-17	2893-2903	activation	abstract[158]|abstract[159]	giv[158]|new[159]	_	_
16-18	2904-2914	represents	abstract[158]	giv[158]	_	_
16-19	2915-2918	the	abstract[158]|abstract[160]	giv[158]|new[160]	_	_
16-20	2919-2927	hallmark	abstract[158]|abstract[160]	giv[158]|new[160]	_	_
16-21	2928-2930	of	abstract[158]|abstract[160]	giv[158]|new[160]	_	_
16-22	2931-2936	liver	abstract[158]|abstract[160]|object|object[162]	giv[158]|new[160]|giv|giv[162]	coref|coref	17-17[168_162]|21-36
16-23	2937-2945	fibrosis	abstract[158]|abstract[160]|object[162]	giv[158]|new[160]|giv[162]	_	_
16-24	2946-2947	.	_	_	_	_

#Text=Secondly , we evaluated whether the miRNAs differentially expressed in insulin resistant HSCs could impact on NAFLD-related fibrosis by using an experimental model of IR-NASH .
17-1	2948-2956	Secondly	_	_	_	_
17-2	2957-2958	,	_	_	_	_
17-3	2959-2961	we	person	giv	ana	19-8
17-4	2962-2971	evaluated	_	_	_	_
17-5	2972-2979	whether	_	_	_	_
17-6	2980-2983	the	abstract[164]	giv[164]	coref	18-19[0_164]
17-7	2984-2990	miRNAs	abstract[164]	giv[164]	_	_
17-8	2991-3005	differentially	abstract[164]	giv[164]	_	_
17-9	3006-3015	expressed	abstract[164]	giv[164]	_	_
17-10	3016-3018	in	abstract[164]	giv[164]	_	_
17-11	3019-3026	insulin	abstract[164]|substance|abstract[166]	giv[164]|giv|giv[166]	coref|coref	18-41|20-21[0_166]
17-12	3027-3036	resistant	abstract[164]|abstract[166]	giv[164]|giv[166]	_	_
17-13	3037-3041	HSCs	abstract[164]|abstract[166]	giv[164]|giv[166]	_	_
17-14	3042-3047	could	_	_	_	_
17-15	3048-3054	impact	_	_	_	_
17-16	3055-3057	on	_	_	_	_
17-17	3058-3071	NAFLD-related	event|object[168]	new|giv[168]	_	_
17-18	3072-3080	fibrosis	object[168]	giv[168]	_	_
17-19	3081-3083	by	_	_	_	_
17-20	3084-3089	using	_	_	_	_
17-21	3090-3092	an	abstract[169]	new[169]	_	_
17-22	3093-3105	experimental	abstract[169]	new[169]	_	_
17-23	3106-3111	model	abstract[169]	new[169]	_	_
17-24	3112-3114	of	abstract[169]	new[169]	_	_
17-25	3115-3122	IR-NASH	abstract[169]|abstract	new[169]|new	_	_
17-26	3123-3124	.	_	_	_	_

#Text=Thus , to investigate the independent contribution of IR and NASH that is usually intertwined in patients on miRNAs expression , IR was induced in mice by haploinsufficiency for InsR ( InsR+/− ) , which determines an impairment of hepatic insulin signaling recapitulating that has been observed in NAFLD patients .
18-1	3125-3129	Thus	_	_	_	_
18-2	3130-3131	,	_	_	_	_
18-3	3132-3134	to	_	_	_	_
18-4	3135-3146	investigate	_	_	_	_
18-5	3147-3150	the	abstract[171]	new[171]	_	_
18-6	3151-3162	independent	abstract[171]	new[171]	_	_
18-7	3163-3175	contribution	abstract[171]	new[171]	_	_
18-8	3176-3178	of	abstract[171]	new[171]	_	_
18-9	3179-3181	IR	abstract[171]|abstract	new[171]|giv	coref	18-22
18-10	3182-3185	and	abstract[171]	new[171]	_	_
18-11	3186-3190	NASH	abstract[171]|abstract	new[171]|giv	coref	19-5[187_0]
18-12	3191-3195	that	abstract[171]	new[171]	_	_
18-13	3196-3198	is	abstract[171]	new[171]	_	_
18-14	3199-3206	usually	abstract[171]	new[171]	_	_
18-15	3207-3218	intertwined	abstract[171]	new[171]	_	_
18-16	3219-3221	in	abstract[171]	new[171]	_	_
18-17	3222-3230	patients	abstract[171]|person	new[171]|giv	coref	18-49[186_0]
18-18	3231-3233	on	abstract[171]	new[171]	_	_
18-19	3234-3240	miRNAs	abstract[171]|abstract|abstract[176]	new[171]|giv|giv[176]	coref|coref	20-5[197_176]|20-8[198_0]
18-20	3241-3251	expression	abstract[171]|abstract[176]	new[171]|giv[176]	_	_
18-21	3252-3253	,	_	_	_	_
18-22	3254-3256	IR	abstract	giv	coref	19-25
18-23	3257-3260	was	_	_	_	_
18-24	3261-3268	induced	_	_	_	_
18-25	3269-3271	in	_	_	_	_
18-26	3272-3276	mice	animal	new	coref	21-24[218_0]
18-27	3277-3279	by	_	_	_	_
18-28	3280-3298	haploinsufficiency	abstract[179]	new[179]	_	_
18-29	3299-3302	for	abstract[179]	new[179]	_	_
18-30	3303-3307	InsR	abstract[179]|abstract	new[179]|giv	appos	18-32
18-31	3308-3309	(	_	_	_	_
18-32	3310-3317	InsR+/−	abstract	giv	coref	21-10
18-33	3318-3319	)	_	_	_	_
18-34	3320-3321	,	_	_	_	_
18-35	3322-3327	which	_	_	_	_
18-36	3328-3338	determines	_	_	_	_
18-37	3339-3341	an	abstract[182]	new[182]	_	_
18-38	3342-3352	impairment	abstract[182]	new[182]	_	_
18-39	3353-3355	of	abstract[182]	new[182]	_	_
18-40	3356-3363	hepatic	abstract[182]|abstract[184]	new[182]|giv[184]	coref	22-15[229_184]
18-41	3364-3371	insulin	abstract[182]|substance|abstract[184]	new[182]|giv|giv[184]	coref	21-24
18-42	3372-3381	signaling	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
18-43	3382-3396	recapitulating	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
18-44	3397-3401	that	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
18-45	3402-3405	has	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
18-46	3406-3410	been	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
18-47	3411-3419	observed	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
18-48	3420-3422	in	_	_	_	_
18-49	3423-3428	NAFLD	abstract|person[186]	giv|giv[186]	coref	21-36[222_0]
18-50	3429-3437	patients	person[186]	giv[186]	_	_
18-51	3438-3439	.	_	_	_	_

#Text=Conversely , to model fibrogenic NASH , we exploited the methionine choline deficient ( MCD ) diet , which impairs phospholipid metabolism without altering IR .
19-1	3440-3450	Conversely	_	_	_	_
19-2	3451-3452	,	_	_	_	_
19-3	3453-3455	to	_	_	_	_
19-4	3456-3461	model	_	_	_	_
19-5	3462-3472	fibrogenic	abstract[187]	giv[187]	_	_
19-6	3473-3477	NASH	abstract[187]	giv[187]	_	_
19-7	3478-3479	,	_	_	_	_
19-8	3480-3482	we	person	giv	ana	20-3
19-9	3483-3492	exploited	_	_	_	_
19-10	3493-3496	the	abstract[192]	new[192]	_	_
19-11	3497-3507	methionine	substance|abstract[192]	new|new[192]	_	_
19-12	3508-3515	choline	substance|abstract[192]	new|new[192]	_	_
19-13	3516-3525	deficient	abstract[192]	new[192]	_	_
19-14	3526-3527	(	abstract[192]	new[192]	_	_
19-15	3528-3531	MCD	abstract|abstract[192]	new|new[192]	_	_
19-16	3532-3533	)	abstract[192]	new[192]	_	_
19-17	3534-3538	diet	abstract[192]	new[192]	_	_
19-18	3539-3540	,	abstract[192]	new[192]	_	_
19-19	3541-3546	which	abstract[192]	new[192]	_	_
19-20	3547-3554	impairs	abstract[192]	new[192]	_	_
19-21	3555-3567	phospholipid	abstract[192]|object|abstract[194]	new[192]|new|new[194]	coref	22-18[231_194]
19-22	3568-3578	metabolism	abstract[192]|abstract[194]	new[192]|new[194]	_	_
19-23	3579-3586	without	_	_	_	_
19-24	3587-3595	altering	_	_	_	_
19-25	3596-3598	IR	abstract	giv	coref	22-38
19-26	3599-3600	.	_	_	_	_

#Text=Finally , we tested the expression of the candidate miRNAs in immortalized human hepatoma cells ( HepG2 ) and in HSCs ( LX-2 ) in the presence or absence of miRNA mimics .
20-1	3601-3608	Finally	_	_	_	_
20-2	3609-3610	,	_	_	_	_
20-3	3611-3613	we	person	giv	ana	21-3
20-4	3614-3620	tested	_	_	_	_
20-5	3621-3624	the	abstract[197]	giv[197]	coref	21-15[215_197]
20-6	3625-3635	expression	abstract[197]	giv[197]	_	_
20-7	3636-3638	of	abstract[197]	giv[197]	_	_
20-8	3639-3642	the	abstract[197]|abstract[198]	giv[197]|giv[198]	_	_
20-9	3643-3652	candidate	abstract[197]|abstract[198]	giv[197]|giv[198]	_	_
20-10	3653-3659	miRNAs	abstract[197]|abstract[198]	giv[197]|giv[198]	_	_
20-11	3660-3662	in	abstract[197]	giv[197]	_	_
20-12	3663-3675	immortalized	abstract[197]|animal[200]	giv[197]|giv[200]	_	_
20-13	3676-3681	human	abstract[197]|animal[200]	giv[197]|giv[200]	_	_
20-14	3682-3690	hepatoma	abstract[197]|animal|animal[200]	giv[197]|new|giv[200]	_	_
20-15	3691-3696	cells	abstract[197]|animal[200]	giv[197]|giv[200]	_	_
20-16	3697-3698	(	_	_	_	_
20-17	3699-3704	HepG2	abstract	new	coref	23-6
20-18	3705-3706	)	_	_	_	_
20-19	3707-3710	and	_	_	_	_
20-20	3711-3713	in	_	_	_	_
20-21	3714-3718	HSCs	abstract	giv	appos	20-23
20-22	3719-3720	(	_	_	_	_
20-23	3721-3725	LX-2	abstract	giv	coref	21-10[211_0]
20-24	3726-3727	)	_	_	_	_
20-25	3728-3730	in	_	_	_	_
20-26	3731-3734	the	abstract[204]	giv[204]	_	_
20-27	3735-3743	presence	abstract[204]	giv[204]	_	_
20-28	3744-3746	or	_	_	_	_
20-29	3747-3754	absence	abstract[205]	new[205]	_	_
20-30	3755-3757	of	abstract[205]	new[205]	_	_
20-31	3758-3763	miRNA	abstract[205]|abstract|abstract[207]	new[205]|giv|new[207]	_	_
20-32	3764-3770	mimics	abstract[205]|abstract[207]	new[205]|new[207]	_	_
20-33	3771-3772	.	_	_	_	_

#Text=Here , we showed that miR-101-3p was downregulated in InsR+/− HSCs and hepatocytes , its expression was reduced even in total livers of insulin resistant mice , and it was associated with all stages of liver disease .
21-1	3773-3777	Here	_	_	_	_
21-2	3778-3779	,	_	_	_	_
21-3	3780-3782	we	person	giv	_	_
21-4	3783-3789	showed	_	_	_	_
21-5	3790-3794	that	_	_	_	_
21-6	3795-3805	miR-101-3p	abstract	new	ana	21-15
21-7	3806-3809	was	_	_	_	_
21-8	3810-3823	downregulated	_	_	_	_
21-9	3824-3826	in	_	_	_	_
21-10	3827-3834	InsR+/−	abstract|abstract[211]|abstract[212]	giv|giv[211]|giv[212]	coref|coref	21-10[212_211]|23-8[0_212]
21-11	3835-3839	HSCs	abstract[211]|abstract[212]	giv[211]|giv[212]	_	_
21-12	3840-3843	and	abstract[212]	giv[212]	_	_
21-13	3844-3855	hepatocytes	abstract[212]|animal	giv[212]|giv	_	_
21-14	3856-3857	,	_	_	_	_
21-15	3858-3861	its	abstract|abstract[215]	giv|giv[215]	ana	21-29
21-16	3862-3872	expression	abstract[215]	giv[215]	_	_
21-17	3873-3876	was	_	_	_	_
21-18	3877-3884	reduced	_	_	_	_
21-19	3885-3889	even	object[216]	new[216]	_	_
21-20	3890-3892	in	object[216]	new[216]	_	_
21-21	3893-3898	total	object[216]	new[216]	_	_
21-22	3899-3905	livers	object[216]	new[216]	_	_
21-23	3906-3908	of	object[216]	new[216]	_	_
21-24	3909-3916	insulin	object[216]|substance|animal[218]	new[216]|giv|giv[218]	coref	22-15
21-25	3917-3926	resistant	object[216]|animal[218]	new[216]|giv[218]	_	_
21-26	3927-3931	mice	object[216]|animal[218]	new[216]|giv[218]	_	_
21-27	3932-3933	,	_	_	_	_
21-28	3934-3937	and	_	_	_	_
21-29	3938-3940	it	abstract	giv	coref	22-11
21-30	3941-3944	was	_	_	_	_
21-31	3945-3955	associated	_	_	_	_
21-32	3956-3960	with	_	_	_	_
21-33	3961-3964	all	abstract[220]	new[220]	_	_
21-34	3965-3971	stages	abstract[220]	new[220]	_	_
21-35	3972-3974	of	abstract[220]	new[220]	_	_
21-36	3975-3980	liver	abstract[220]|object|abstract[222]	new[220]|giv|giv[222]	coref	22-36[0_222]
21-37	3981-3988	disease	abstract[220]|abstract[222]	new[220]|giv[222]	_	_
21-38	3989-3990	.	_	_	_	_

#Text=Consistently with these results , target prediction analysis revealed that miR-101-3p is involved in insulin signaling , lipid metabolism , cell proliferation , fibrogenesis , and cancer susceptibility , possibly representing a molecular signature in NAFLD during IR .
22-1	3991-4003	Consistently	_	_	_	_
22-2	4004-4008	with	_	_	_	_
22-3	4009-4014	these	abstract[223]	new[223]	_	_
22-4	4015-4022	results	abstract[223]	new[223]	_	_
22-5	4023-4024	,	_	_	_	_
22-6	4025-4031	target	abstract|abstract[225]|abstract[226]	new|new[225]|new[226]	_	_
22-7	4032-4042	prediction	abstract[225]|abstract[226]	new[225]|new[226]	_	_
22-8	4043-4051	analysis	abstract[226]	new[226]	_	_
22-9	4052-4060	revealed	_	_	_	_
22-10	4061-4065	that	_	_	_	_
22-11	4066-4076	miR-101-3p	abstract	giv	coref	23-3
22-12	4077-4079	is	_	_	_	_
22-13	4080-4088	involved	_	_	_	_
22-14	4089-4091	in	_	_	_	_
22-15	4092-4099	insulin	substance|abstract[229]	giv|giv[229]	_	_
22-16	4100-4109	signaling	abstract[229]	giv[229]	_	_
22-17	4110-4111	,	_	_	_	_
22-18	4112-4117	lipid	abstract|abstract[231]	giv|giv[231]	_	_
22-19	4118-4128	metabolism	abstract[231]	giv[231]	_	_
22-20	4129-4130	,	_	_	_	_
22-21	4131-4135	cell	place|abstract[233]	new|new[233]	coref	23-10[0_233]
22-22	4136-4149	proliferation	abstract[233]	new[233]	_	_
22-23	4150-4151	,	_	_	_	_
22-24	4152-4164	fibrogenesis	abstract	giv	_	_
22-25	4165-4166	,	_	_	_	_
22-26	4167-4170	and	_	_	_	_
22-27	4171-4177	cancer	abstract|abstract[236]	giv|new[236]	_	_
22-28	4178-4192	susceptibility	abstract[236]	new[236]	_	_
22-29	4193-4194	,	_	_	_	_
22-30	4195-4203	possibly	_	_	_	_
22-31	4204-4216	representing	_	_	_	_
22-32	4217-4218	a	abstract[237]	new[237]	_	_
22-33	4219-4228	molecular	abstract[237]	new[237]	_	_
22-34	4229-4238	signature	abstract[237]	new[237]	_	_
22-35	4239-4241	in	abstract[237]	new[237]	_	_
22-36	4242-4247	NAFLD	abstract[237]|abstract	new[237]|giv	_	_
22-37	4248-4254	during	abstract[237]	new[237]	_	_
22-38	4255-4257	IR	abstract[237]|abstract	new[237]|giv	_	_
22-39	4258-4259	.	_	_	_	_

#Text=Furthermore , miR-101-3p overexpression in HepG2 and LX-2 reduced proliferation , migration , and invasiveness , regulating pro-fibrotic and pro-carcinogenic markers .
23-1	4260-4271	Furthermore	_	_	_	_
23-2	4272-4273	,	_	_	_	_
23-3	4274-4284	miR-101-3p	abstract|abstract[241]	giv|new[241]	_	_
23-4	4285-4299	overexpression	abstract[241]	new[241]	_	_
23-5	4300-4302	in	abstract[241]	new[241]	_	_
23-6	4303-4308	HepG2	abstract[241]|abstract	new[241]|giv	_	_
23-7	4309-4312	and	abstract[241]	new[241]	_	_
23-8	4313-4317	LX-2	abstract[241]|abstract	new[241]|giv	_	_
23-9	4318-4325	reduced	_	_	_	_
23-10	4326-4339	proliferation	abstract	giv	_	_
23-11	4340-4341	,	_	_	_	_
23-12	4342-4351	migration	abstract	new	_	_
23-13	4352-4353	,	_	_	_	_
23-14	4354-4357	and	_	_	_	_
23-15	4358-4370	invasiveness	abstract	new	_	_
23-16	4371-4372	,	_	_	_	_
23-17	4373-4383	regulating	_	_	_	_
23-18	4384-4396	pro-fibrotic	abstract[247]	new[247]	_	_
23-19	4397-4400	and	abstract[247]	new[247]	_	_
23-20	4401-4417	pro-carcinogenic	abstract[247]	new[247]	_	_
23-21	4418-4425	markers	abstract[247]	new[247]	_	_
23-22	4426-4427	.	_	_	_	_
